Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

With The End Of Pfizergan, Pfizer Has To Grow It Alone

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors are wondering what Pfizer might do next – and especially whether or not it will split – after the company is outmaneuvered by the US government and ends its ambition to merge with Allergan.


Related Content

Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
Pfizer Oncology Strategy: An Investment Starts To Pay Off


Related Companies

Related Deals